From the Swedish Medical Center and University of Washington, Seattle, Washington; Novartis Pharmaceuticals Corp., East Hanover, New Jersey; Corrona LLC, Waltham, Massachusetts; University of California San Diego, La Jolla, California; Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center, Rochester; New York University School of Medicine, New York, New York, USA.
P.J. Mease, MD, Swedish Medical Center and University of Washington; J.B. Palmer, PharmD, Novartis Pharmaceuticals Corp.; M. Liu, PhD, Corrona LLC; C. Karki, MPH, Corrona LLC; A. Kavanaugh, MD, University of California San Diego; R. Pandurengan, PhD, Corrona LLC; C.T. Ritchlin, MD, MPH, Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center; J.D. Greenberg, MD, MPH, Corrona LLC, and New York University School of Medicine.
J Rheumatol. 2018 Oct;45(10):1389-1396. doi: 10.3899/jrheum.171094. Epub 2018 Jul 1.
We analyzed the characteristics of patients with psoriatic arthritis (PsA) with and without axial involvement in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
All patients were included who had PsA and data on axial involvement, defined as physician-reported presence of spinal involvement at enrollment, and/or radiograph or magnetic resonance imaging showing sacroiliitis. Demographics, clinical measures, patient-reported outcomes, and treatment characteristics were assessed at enrollment.
Of 1530 patients with PsA, 192 (12.5%) had axial involvement and 1338 (87.5%) did not. Subgroups were similar in sex, race, body mass index, disease duration, presence of dactylitis, and prevalence of most comorbidities. However, patients with axial involvement were younger and more likely to have enthesitis, a history of depression, and more frequently used biologics at enrollment. They were also more likely to have moderate/severe psoriasis (body surface area ≥ 3%, 42.5% vs 31.5%) and significantly worse disease as measured by a lower prevalence of minimal disease activity (30.1% vs 46.2%) and higher nail psoriasis scores [visual analog scale (VAS) 11.4 vs 6.5], enthesitis counts (5.1 vs 3.4), Bath Ankylosing Spondylitis Disease Activity Index (4.7 vs 3.5) scores, Bath Ankylosing Spondylitis Functional Index (3.8 vs 2.5) scores, C-reactive protein levels (4.1 vs 2.4 mg/l), and scores for physical function (Health Assessment Questionnaire, 0.9 vs 0.6), pain (VAS, 47.7 vs 36.2), and fatigue (VAS, 50.2 vs 38.6).
Presence of axial involvement was associated with a higher likelihood of moderate/severe psoriasis, with higher disease activity and greater effect on quality of life. These findings highlight the importance of monitoring patients with PsA for signs of axial symptoms or spinal involvement.
我们分析了美国 Corrona 银屑病关节炎/脊柱关节炎注册研究中伴或不伴轴性受累的银屑病关节炎(PsA)患者的特征。
纳入所有存在 PsA 且有轴性受累数据的患者,轴性受累定义为入组时医生报告的脊柱受累,和/或影像学显示骶髂关节炎。在入组时评估了患者的人口统计学、临床指标、患者报告的结局和治疗特征。
在 1530 例 PsA 患者中,192 例(12.5%)存在轴性受累,1338 例(87.5%)不存在。两组在性别、种族、体重指数、疾病持续时间、存在指(趾)炎以及大多数合并症的患病率方面相似。然而,存在轴性受累的患者更年轻,更有可能出现附着点炎、抑郁史,且入组时更频繁地使用生物制剂。他们也更有可能患有中重度银屑病(体表面积≥3%,42.5%比 31.5%),疾病严重程度显著更高,表现在更低的疾病活动度低(30.1%比 46.2%)和更高的指甲银屑病评分[视觉模拟量表(VAS)11.4 比 6.5]、附着点炎计数[5.1 比 3.4]、 Bath 强直性脊柱炎疾病活动指数(BASDAI)评分[4.7 比 3.5]、 Bath 强直性脊柱炎功能指数(BASFI)评分[3.8 比 2.5]、C 反应蛋白水平[4.1 比 2.4 mg/L]和身体功能评分[健康评估问卷(HAQ),0.9 比 0.6]、疼痛评分(VAS,47.7 比 36.2)和疲劳评分(VAS,50.2 比 38.6)。
存在轴性受累与中重度银屑病的发生可能性更高相关,与更高的疾病活动度和更大的生活质量影响相关。这些发现强调了监测银屑病关节炎患者出现轴性症状或脊柱受累迹象的重要性。